CMRX Insider Trading
Insider Ownership Percentage: 13.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $92,241.70
Chimerix Share Price & Price History
Current Price: $8.51
Price Change: ▼ Price Decrease of -0.005 (-0.06%)
As of 04/1/2025 03:22 PM ET
Chimerix Insider Trading History
Chimerix Institutional Trading History
Data available starting January 2016
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Read More on Chimerix
Volume
1,244,480 shs
Average Volume
2,126,034 shs
Market Capitalization
$797.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.32
Who are the company insiders with the largest holdings of Chimerix?
Chimerix's top insider investors include:
- Michael T Andriole (CEO)
- Michael T Andriole (CFO)
- Michael Albert Alrutz (SVP)
- Michelle Laspaluto (CFO)
- Allen S Melemed (Insider)
- David Jakeman (VP)
- Fred A Middleton (Director)
- Martha J Demski (Director)
- Robert J Meyer (Director)
Learn More about top insider investors at Chimerix.